Vanguard Group Inc. Acquires 222,652 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Vanguard Group Inc. grew its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 18.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,406,431 shares of the company's stock after purchasing an additional 222,652 shares during the quarter. Vanguard Group Inc. owned approximately 4.69% of Keros Therapeutics worth $44,837,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its stake in Keros Therapeutics by 13.0% in the first quarter. JPMorgan Chase & Co. now owns 37,528 shares of the company's stock valued at $2,041,000 after acquiring an additional 4,329 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Keros Therapeutics by 55.0% in the first quarter. MetLife Investment Management LLC now owns 8,455 shares of the company's stock valued at $460,000 after purchasing an additional 2,999 shares during the last quarter. Rhumbline Advisers grew its holdings in Keros Therapeutics by 14.3% during the first quarter. Rhumbline Advisers now owns 15,886 shares of the company's stock valued at $864,000 after purchasing an additional 1,984 shares during the period. BlackRock Inc. increased its position in Keros Therapeutics by 0.9% in the first quarter. BlackRock Inc. now owns 1,298,046 shares of the company's stock worth $70,588,000 after buying an additional 11,520 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its stake in shares of Keros Therapeutics by 57.6% in the first quarter. Allianz Asset Management GmbH now owns 75,391 shares of the company's stock valued at $4,100,000 after buying an additional 27,544 shares during the period. 71.56% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wedbush reiterated an "outperform" rating and set a $86.00 price target on shares of Keros Therapeutics in a research note on Thursday, February 29th. William Blair reiterated an "outperform" rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. HC Wainwright restated a "buy" rating and set a $100.00 price target on shares of Keros Therapeutics in a research note on Friday, March 1st. Piper Sandler reiterated an "overweight" rating and issued a $105.00 price objective on shares of Keros Therapeutics in a research note on Wednesday, March 27th. Finally, Truist Financial reissued a "buy" rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 13th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $86.00.

Keros Therapeutics Stock Down 4.7 %

NASDAQ:KROS traded down $2.98 during trading hours on Wednesday, hitting $60.83. 272,976 shares of the company's stock traded hands, compared to its average volume of 433,109. The firm has a market cap of $2.19 billion, a P/E ratio of -12.27 and a beta of 1.26. The business's fifty day simple moving average is $62.90 and its two-hundred day simple moving average is $45.67. Keros Therapeutics, Inc. has a 52 week low of $27.02 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Friday, March 1st. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $0.14 million for the quarter. During the same period last year, the firm earned ($1.09) earnings per share. On average, analysts expect that Keros Therapeutics, Inc. will post -5.11 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.